Arthneeti
Sale is live|00:00:00

Aprameya Engineering Ltd Q1 FY26 Earnings Analysis

Published 16 Jul 2026 | Healthcare Equipment & Supplies | Market Cap: ₹445 Cr

Price

150

Market Cap

₹445 Cr

P/E Ratio

18.1

Revenue Rank

Rank 3

Margin Rank

Rank 3

Earnings Summary

- Aprameya aims to achieve sustained growth faster than the healthcare infrastructure industry's CAGR of 22% over the last decade. - Aprameya aims to sustain strong growth, leveraging proprietary turnkey projects and expanding services.

📊 Revenue & Sales Performance

Rank 3

- Aprameya aims to achieve sustained growth faster than the healthcare infrastructure industry's CAGR of 22% over the last decade. - The company is optimistic about securing good orders across multiple states due to its proprietary products and strong entry barriers in tenders. - With an expanding geographic footprint into states like Bihar, Uttarakhand, Assam, Chhattisgarh, Daman, and Sikkim, Aprameya is positioned for scalable growth. - Order book stood at INR 60 crores, with expectations for continuous order inflow driven by unique, lifesaving proprietary solutions. - Revenue grew by 108% YoY to INR 136 crores in FY25, backed by a higher share of high-margin turnkey projects. - Management expresses confidence in maintaining and improving margins and increasing service contracts, which contribute recurring revenue. - Future guidance hints at steady revenue growth, though no specific growth percentage is promised.

📈 Profitability & Margins

Rank 3

- Aprameya aims to sustain strong growth, leveraging proprietary turnkey projects and expanding services. - The company is confident in maintaining current margin levels, focusing on high-margin projects and selective bidding. - EBITDA margin improved to 18% in FY25; this level is expected to be sustainable with disciplined cost and capital management. - PAT margin increased to 12% in FY25, reflecting operational efficiencies. - Growth driven by geographic expansion into underpenetrated states like Bihar, Assam, and Uttarakhand. - Expanding order book with INR60 crores executing over 5-6 months and targeting high-margin contracts. - Focus on increasing services and CMC contracts post three-year warranty completion, which have higher margins. - Entering specialized proprietary product markets (e.g., EP lab systems) to boost margins and revenues. - Cash flow improvements expected due to reducing debtor cycles. - Management confident in delivering sustained earnings growth but cautious on aggressive margin guidance without contract clarity.

🏗️ Capital Expenditure Plans

Yes

- Capex for expansion into new states will be gradual, not a one-time large investment; focus is on brownfield projects (working inside existing buildings) rather than greenfield projects. - Capital investments in new states will be phased over 2-3 months per project rather than upfront heavy capital. - The company plans to control capex carefully to avoid hampering cash flow and maintain a balanced inflow and outflow ratio. - Specific capex figures are not shared publicly; investors are encouraged to contact the IR agency for detailed queries. - Debt levels have been declining year-on-year, and the company aims to manage working capital efficiently during expansion to avoid raising significant new debt. - Expansion will be selective, focusing only on projects where margins, revenue, and credit terms are comfortable to secure.

💰 Fundraising & Capital Structure

Yes

- The management did not mention any specific plans for raising new debt or equity during the expansion. - They emphasized reducing the debtor cycle to improve cash flow and funding projects "as per our requirement only." - Capex for expansion will be gradual and aligned with cash inflows from ongoing projects, not requiring large upfront investments. - For exact capex figures or potential fundraising details, the management directed investors to contact their IR agency, Stellar, for specific queries. - The company aims to maintain manageable debt levels and has been successfully reducing net debt year-on-year. - Overall, the approach is cautious, focusing on operational cash flow and selective project bidding without immediate plans to raise significant external funds.

📋 Order Book & Pipeline

Yes

- Current order book: Approximately INR 60 crores. - Execution timeline: Orders expected to be completed within 5 to 6 months. - Geographic split: 60%-70% from Maharashtra, 10%-20% from Rajasthan, remaining from Gujarat. - Growth outlook: Company optimistic about securing additional orders due to sector growth and strong entry barriers. - Previous projects and order pipeline suggest sustained opportunities for expansion across multiple states. - The company expects to maintain steady order inflow aligned with industry CAGR growth trends.

Key Metrics

Revenue

Rank 3

Margin

Rank 3

Capex

Yes

Fundraise

Yes

Order Book

Yes

Frequently Asked Questions

What were Aprameya Engineering Ltd Q1 FY26 results?

- Aprameya aims to achieve sustained growth faster than the healthcare infrastructure industry's CAGR of 22% over the last decade. - Aprameya aims to sustain strong growth, leveraging proprietary turnkey projects and expanding services.

What is Aprameya Engineering Ltd share price analysis?

Aprameya Engineering Ltd currently shows a below-average growth signal. The stock trades at a P/E of 18.1 with a market cap of ₹445. Investors should review the full earnings analysis for detailed insights.

Is Aprameya Engineering Ltd planning capital expenditure?

- Capex for expansion into new states will be gradual, not a one-time large investment; focus is on brownfield projects (working inside existing buildings) rather than greenfield projects.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.